Compare Intel Corp (INTC) vs Viatris Inc (VTRS) Price & Performance

Intel CorpTrade

Viatris IncTrade

Price performance (Past 24H)

Key statistics

Intel Corp vs Viatris Inc — how do they compare? Intel Corp trades at $99.71 (market cap $491.89B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Intel Corp is far larger — about 26.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

	INTC	VTRS
Market Cap	$491.89B	$18.69B
Volume	43,552,012	—
Sector	Technology	Health
52-Week High	$140.94	$17.86
52-Week Low	$21.81	$9.49
Enterprise Value	$512.70B	$30.81B
Dividend Yield	2.24%	2.95%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INTC

Polen 5Perspectives Large Growth Portfolio outperforms Russell 1000 Growth with 26.63% return in Q2 2026Seeking Alpha · 12 hours agoBullish Intel stock upgraded to Buy as Q2 revenue jumps 25%, margins expand, and outlook beats expectations.Seeking Alpha · 1 day agoBullish Intel stock soars 370% in a year, fueled by Nvidia partnership and AI demand.Finbold · 1 day agoBullish View details →

VTRS

View details →

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).